Skip to main content
A

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2026-04-15 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于回购注销部分限制性股票减资通知债权人的公告
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement by Xiamen Aide Biomed regarding the repurchase and cancellation of restricted shares under its 2023 incentive plan and the consequent reduction in registered capital (from RMB 391,536,144 to RMB 390,105,169). It also includes a creditor notice for the capital reduction process. This is not a proxy, earnings release, board change, or AGM material, but rather a capital change announcement. Therefore, it fits the "Share Issue/Capital Change" category (SHA).
2026-04-15 Chinese
关于会计师事务所履职情况的评估报告
Audit Report / Information Classification · 1% confidence The document is a standalone evaluation report on the performance of the appointed accounting firm (Lixin) for the 2025 audit. It is not a full annual report or earnings release but an audit-related disclosure assessing auditor conduct and compliance. This aligns with the ‘Audit Report / Information’ category.
2026-04-15 Chinese
关于拟续聘会计师事务所的公告
Regulatory Filings Classification · 1% confidence The document is an official announcement by Xiamen Aide Biotech detailing the proposed reappointment (续聘) of its external auditing firm (立信会计师事务所) for the 2026 audit term, including auditor credentials, independence confirmations, board and audit committee resolutions. It is not the audit report itself, nor a proxy statement, dividend notice, earnings release, or management report. This notice falls under general regulatory announcements regarding auditor appointments, which do not have a dedicated category, so it is classified as a Regulatory Filing (RNS).
2026-04-15 Chinese
董事会薪酬与考核委员会关于回购注销2023年限制性股票激励计划部分限制性股票的核查意见
Transaction in Own Shares Classification · 1% confidence The document is an official announcement by the board’s remuneration and assessment committee regarding the repurchase and cancellation of restricted shares under the 2023 restricted stock incentive plan. This clearly describes the company buying back its own shares (restricted stock) and cancelling them. Such transactions fall under the category “Transaction in Own Shares” (POS).
2026-04-15 Chinese
关于使用闲置自有资金进行现金管理的公告
Regulatory Filings Classification · 0% confidence The document is a routine corporate announcement by Xiamen Aide Biotech regarding the board approval to use up to RMB 1.8 billion of idle self-owned funds for cash management over a 12-month period. It is not an earnings release, audit report, annual or interim report, nor does it concern capital raising, share issue, M&A, delisting, insider dealing, dividend, proxy or voting results. It is a standard regulatory disclosure of a funding allocation decision that does not fit any of the specialized categories, so it defaults to the general Regulatory Filings category (RNS).
2026-04-15 Chinese
独立董事2025年度述职报告（吴乔）
Governance Information Classification · 1% confidence The document is an annual performance report (“述职报告”) by an independent director, detailing his governance duties, attendance at board/committee meetings, internal control oversight, compliance with listing rules, and protection of shareholders’ rights. It is not an earnings release, financial report, or vote results announcement, but rather a corporate governance report on board responsibilities and practices. This aligns with the “Governance Information” category (CGR).
2026-04-15 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.